Hydroxychloroquine in COVID-19 Patients

Official Title

Use of Hydroxychloroquine in Patients With COVID-19: A Randomized Controlled Clinical Trial

Brief Summary

Many reports argued about the possible beneficial effects of Hydroxychloroquine in treating COVID-19 patients and this study was designed to investigate this claim

Status

Unknown status

Conditions

COVID-19

Interventions

Drug: Hydroxychloroquine

400mg BD first day then 200 mg BD for 5 days

Eligibility Criteria

Inclusion Criteria:

Confirmed cases of SARS-CoV-2 by PCR

Exclusion Criteria:

less than 18 years old known hypersensitivity to the drug

Eligibility Gender

All

Eligibility Age

Minimum: 18 Years ~ Maximum: 70 Years

Countries

Saudi Arabia

Locations

SNH
Mecca, Saudi Arabia

Investigator: Samah Lutfy, MD
Contact: +966581244415
omar1star2008@yahoo.com

Contacts

Samah M Lutfy, MD
+966581244415
omar1star2008@yahoo.com

NCT Number

NCT04394442

MeSH Terms

COVID-19

Hydroxychloroquine

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Samah Lutfy

Hydroxychloroquine in COVID-19 Patients

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA